Association of angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea in a Chinese population: A meta-analysis

Jian Xu1*, Jiming Chen2*, Yilu Li2*, Dandan Zhang1* and Xiaoli Li1

Abstract
Introduction: Many studies have investigated the association between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and susceptibility to obstructive sleep apnoea (OSA). However, few have confirmed the relationship between ACE and OSA in the Chinese population. We performed a meta-analysis of studies relating the ACE I/D polymorphism to the risk of OSA in a Chinese population.

Methods: We evaluated eligible published studies from several databases for this meta-analysis. Subgroup analyses were performed for hypertension. Pooled odds ratios and 95% confidence intervals were calculated using a fixed- or random-effects model.

Results: Ten studies were identified to analyse the association between ACE I/D polymorphism and OSA risk. No marked associations were found in any genetic model (p>0.05). Subgroup analysis showed an association with hypertension (D vs. I, DD vs. II, ID vs. DD+II, DD+ID vs. II, ID vs. II; p<0.05), which was confirmed by sensitivity analyses. No obvious publication bias was found using Egger’s test (p>0.05).

Conclusions: The ACE I/D polymorphism was not associated with an increased risk of OSA in a Chinese population. However, within the hypertensive subgroup, we detected a significant association between the ACE polymorphism and OSA. More case-control investigations are required.

Keywords
Angiotensin-converting enzyme (ACE), obstructive sleep apnoea (OSA), insertion/deletion (I/D) gene, polymorphism, meta-analysis

Date received: 26 December 2019; accepted: 8 May 2020

Introduction
Obstructive sleep apnoea (OSA) has an estimated prevalence of 2% in women and 4% in men.¹ OSA is characterised by repetitive bouts of upper-airway collapse during sleep, resulting in intermittent periods of hypoxia and hypercapnia, fragmented sleep and heightened sympathetic nervous system activity.² Patients with OSA have an increased incidence of various diseases, including insulin resistance, hypertension, stroke, acute myocardial infarct, arrhythmia and cerebrovascular ischaemic complications.³–⁶

Previous studies have indicated that OSA is a complex disorder affected by a combination of genetic, environmental and developmental factors that interact to determine the overall phenotype.⁷ Despite extensive research in this field, the aetiology of most OSA remains unclear, and genetic

¹Department of Respiratory and Critical Care Medicine, Shenzhen Hospital of Southern Medical University, PR China
²Department of Respiratory and Critical Care Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, PR China
*These authors contributed equally to this work.

Corresponding author:
Xiaoli Li, Department of Respiratory and Critical Care Medicine, Shenzhen Hospital of Southern Medical University, Xinhu Road 1333, Baoan District, Shenzhen City, 518101, PR China.
Email: lixiaolinfy@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
polymorphisms have been proposed as susceptibility factors in patients with OSA.5–11

During the past decade, the role of the renin–angiotensin system (RAS) in the development of OSA has generated interest. Angiotensin-converting enzyme (ACE) – the key enzyme in the RAS – is released from the cell membrane.12 ACE is a zinc metallopeptidase that converts angiotensin I to angiotensin II.13

The angiotensin-converting enzyme (ACE) gene consists of either an insertion (I) allele or a deletion (D) allele, forming three possible genotypes: II, ID and DD.14,15 The ACE gene locus is the major locus that determines serum and tissue concentrations of ACE.16,17 Several studies have shown that the ACE I/D polymorphism is a possible risk factor for myocardial infarction,18 overweight/obesity,19 hypertrophic cardiomyopathies20 and hypertension.21

The hypothesis that ACE I/D polymorphisms may play important roles in the risk of OSA in Chinese has also been debated. Many studies have investigated the potential relationship between ACE I/D gene polymorphisms and OSA, but the results have been inconsistent. Some meta-analyses have reported a correlation between ACE I/D gene polymorphisms and OSA, although the results were negative or the subjects were not Chinese.22–25

The ACE I/D polymorphism has been associated with other disorders in the Chinese population.26,27 Therefore, this association should be investigated in Chinese patients and more comparisons should be performed.

To evaluate the association between the ACE I/D polymorphism and the risk of OSA in the Chinese population further, we conducted a meta-analysis by combining genotype data from all eligible studies published to date.

Methods

Publication search

We searched relevant studies from PubMed, Embase, Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI) database, the Wan Fang database and the Weipu database. The search strategy to identify all possible studies involved the use of the following keywords in the abstract: ‘OSAHS’, ‘OSAS’, ‘OSA’, ‘obstructive sleep apnoea syndrome’, ‘obstructive sleep apnoea hypopnoea syndrome’, ‘obstructive sleep apnoea’, ‘angiotensin converting enzyme’ and ‘ACE’. The reference lists of retrieved reviews and articles were searched by hand. If more than one article was published using the same case series, only the study with largest sample size was included. The literature search was updated on 30 July 2019.

Inclusion criteria

The included studies had to meet the following criteria: (a) evaluated ACE mutation status and relationship to OSA in Chinese children or adults; (b) were full-text articles; (c) were case-control studies; (d) had sufficient published data to estimate an odds ratio (OR) and 95% confidence interval (CI); (e) included at least two comparison groups (OSA group vs. control group); (f) mentioned hypertension in the OSA group; and (g) were observational studies published in Chinese or English.

Data extraction and quality evaluation

Two authors independently reviewed the titles, abstracts and full text to assess the articles for compliance with the inclusion criteria. Disagreement was followed by discussion until consensus was reached. Information was carefully extracted from all eligible publications independently by two of the authors according to the inclusion criteria listed above. The following information was extracted from each study: (a) name of the first author; (b) year of publication; (c) sample size of cases and controls; (d) genotype distributions of cases and controls; (e) presence or absence of hypertension; and (f) results of Hardy–Weinberg equilibrium (HWE) test in controls. The quality of the included literature was evaluated using the Newcastle–Ottawa Scale (NOS). According to the NOS evaluation criteria, each included study scored ≥6 stars, indicating that it was of high quality.

Statistical methods

We assessed HWE in the controls for each study using a goodness-of-fit test (chi-square or Fisher’s exact test), and a p-value of <0.05 was considered to indicate significant disequilibrium. ORs with 95% CI were used to assess the strength of association between the ACE I/D gene polymorphism and OSA risk. The pooled ORs were performed for the following comparisons: D versus I, DD versus II, ID versus II; DD+ID versus II; DD versus ID+II and ID versus DD+II. Assumption of heterogeneity was checked by the chi-square-based Q-test. A p-value of >0.1 for the Q-test indicates a lack of heterogeneity among studies. So, the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel–Haenszel method).18 Otherwise, the random-effects model (DerSimonian and Laird method) was used.19

Subgroup analyses were performed for hypertension. The diagnostic standard used for hypertension was according to 2010 Chinese guidelines for the prevention and treatment of hypertension: in the absence of antihypertensive drugs, blood pressure was measured three times on different days. Patients with hypertension were those with a systolic blood pressure ≥140 mmHg or a diastolic blood pressure ≥90 mmHg, or patients who were previously diagnosed with hypertension and were currently using antihypertensive drugs and whose blood pressure was <140/90 mmHg.

An estimate of potential publication bias was carried out by assessing funnel plots, in which the standard error
of log (OR) of each study was plotted against its log (OR). An asymmetric plot indicates possible publication bias. Funnel plot asymmetry was assessed with Egger’s linear regression test on the natural logarithm scale of the OR. The significance of the intercept was determined by the \( t \)-test suggested by Egger (\( p < 0.05 \) was considered indicative of statistically significant publication bias).\(^{28}\) If publication bias existed, the Duval and Tweedie non-parametric ‘trim and fill’ method was used to adjust for it. All statistical tests were performed using Stata v15.0 (StataCorp, College Station, TX).

**Results**

**Study characteristics**

A total of 501 articles were retrieved from PubMed \((n=91)\), Embase \((n=145)\), the Cochrane Library \((n=31)\), CNKI \((n=27)\), the Wanfang database \((n=159)\) and the Weipu database \((n=48)\). Of these, 191 articles published in Chinese or English were excluded because they were duplicates. In addition, 293 articles were excluded for the following reasons: they were review articles, editorials or case reports; the preliminary result was not about the \( ACE \) I/D gene polymorphism or outcome; they investigated the relationship of \( ACE \) inhibitor to disease; or polymorphisms or the \( ACE \) I/D polymorphism did not concern OSA or include Chinese in the study population.

Seventeen investigations were reported on the association of the \( ACE \) I/D gene polymorphism with OSA susceptibility. However, two were published in a language other than Chinese or English, two reported animal experiments, one reported grouping in syndrome differentiation of Traditional Chinese Medicine and two did not include a control group.

Finally, 10 studies were identified to analyse the association between the \( ACE \) I/D gene polymorphism and OSA susceptibility in our review (Figure 1).\(^{29-38}\) One of the

---

**Figure 1. Flow chart of study selection.**
investigations was performed in children. Study characteristics are summarised in Table 1. Genotype distributions in the control groups of the included studies were in agreement with HWE, except for three studies (Table 1). The quality of the studies was assessed using the NOS quality assessment scale; quality scores ranged from 6 to 8 (mean 6.8; Table 1).

### Meta-analysis results

In the meta-analysis of 10 studies, we found obvious between-study heterogeneity in the six comparison models. Thus, the random-effects model was used to calculate pooled ORs with corresponding 95% CIs. The overall result showed that there was no statistically significant association between the ACE gene polymorphism and OSA: D versus I, OR=0.770, 95% CI 0.461–1.287, p=0.319; DD versus II, OR=0.538, 95% CI 0.204–1.419, p=0.211; DD versus DI+II, OR=0.720, 95% CI 0.342–1.516, p=0.388; ID versus DD+II, OR=0.804, 95% CI 0.585–1.106, p=0.181; DD+ID versus DI+II, OR=0.664, 95% CI 0.351–1.257, p=0.209; ID versus DI+II, OR=0.695, 95% CI 0.420–1.149, p=0.156 (Table 2).

### Subgroup analysis

In the subgroup analysis of patients with and without hypertension, significant associations were found in patients with hypertension: D versus I, OR=0.517, 95% CI 0.277–0.966, p=0.039; DD versus II, OR=0.299, 95% CI 0.104–0.864, p=0.026; DD versus DI+II, OR=0.441, 95% CI 0.143–1.362, p=0.155; ID versus DD+II, OR=0.602, 95% CI 0.449–0.808, p=0.001; DD+ID versus II, OR=0.407, 95% CI 0.253–0.654, p=0.000 (Table 2).

### Sensitivity analysis

Sensitivity analysis was carried out to identify potentially influential studies by sequential omission of each individual study. We found statistically similar results after sequentially excluding each study, suggesting high stability of the meta-analysis results.

### Publication bias

To investigate publication bias, Egger’s linear regression was performed for the association between ACE I/D polymorphisms and OSA. We did not detect publication bias of the meta-analysis for the association between the ACE I/D gene polymorphism and OSA risk (p>0.05). There was no obvious asymmetry in the shape of the funnel plots.

### Discussion

OSA is a complex disease caused by multiple genetic and other factors. Recently, epidemiological studies have evaluated the association between the ACE I/D polymorphism and OSA, but the results remain inconclusive. Barcelo et al. reported that ACE I/D polymorphisms were not associated with increased susceptibility to OSA, whereas Chmielewska suggested that the ACE I/D polymorphism was associated with OSA. Therefore, we performed this meta-analysis to investigate whether an association exists between potential polymorphisms of the ACE I/D gene and OSA risk.

The present meta-analysis comprised 10 studies, including 843 cases and 759 controls. Only one study was in children, and our study covered a wide range of the Chinese population. The strength of our meta-analysis is based on the high number of published studies, which allowed us to achieve sufficient statistical power to detect a modest effect estimate. The results indicated that the ACE I/D polymorphism was not associated with elevated OSA risk in the overall study population. This finding was consistent with those from previous meta-analyses, which indicated no association among the Chinese population.

Considering the association of OSA and hypertension, we conducted a subgroup analysis in patients based on the
presence or absence of hypertension. The significant association between this polymorphism and OSA risk in some genotypes in hypertensive patients was consistent with a previous report, but that study included Caucasians and Asians. Lin reported that the \( \text{ACE} \) I/D polymorphism may be a risk factor for OSA with hypertension in Asians, but only four studies were included. Our results also differ from research by Lee et al., which reported no association between this polymorphism and OSA with hypertension. To our knowledge, the previous research differed from our current research because our study targeted only the Chinese population, and subgroup analysis was performed in patients with hypertension.

Heterogeneity is an important issue when performing meta-analyses. Between-study heterogeneity existed in overall comparisons. In the hypertension subgroup analysis, we found that heterogeneity was decreased in the subgroup, suggesting that certain effects of genetic variants are specific to hypertension.

In addition, we obtained statistically similar results in the sensitivity analysis, which sequentially excluded individual studies. Further, we assessed publication bias by using Egger’s test in the present study. These analyses indicated the stability and reliability of the meta-analysis results in our study.

Some limitations of this meta-analysis should be acknowledged. First, the heterogeneity and small sample size may have distorted the meta-analysis, although some of the heterogeneity was resolved in the hypertension subgroup analysis. Second, our results were based on unadjusted effect estimates and confidence intervals, and confounding factors were not controlled. Third, the subgroup results should be interpreted with caution because of the limited statistical power. We could not examine the association of \( \text{ACE} \) I/D polymorphism and OSA activity or clinical features due to the limited amount of data. Despite these limitations, our meta-analysis had some advantages. First, a substantial number of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. Second, the results of the subgroup and sensitivity analyses were not materially altered and did not result in different conclusions, indicating that our results were robust. Third, Egger’s test did not detect any publication bias, indicating that our results were unbiased.

In conclusion, this meta-analysis of 10 studies strongly suggested that the \( \text{ACE} \) I/D polymorphism is not associated with increased risk of OSA in a Chinese population. Subgroup analysis revealed a significant correlation in the hypertension subpopulation. Accordingly, our findings

### Table 2. Meta-analysis of the association between the \( \text{ACE} \) I/D polymorphism and OSA.

| Genetic contrasts | Design | No. of studies | Test of association | Test of heterogeneity |
|-------------------|--------|----------------|---------------------|-----------------------|
|                   |        |                | OR (95% CI)         | Z \( p \) \( I^2 \) (%) | \( p \)         |
| D vs. I           | All    | 10             | 0.770 (0.461–1.287) | 1.00 0.319            | 91.6       0.000 |
|                   | All in HT | 14          | 0.611 (0.397–0.939) | 2.24 0.025            | 88.4       0.000 |
|                   | OSA with HT | 7           | 0.517 (0.277–0.966) | 2.07 0.039            | 86.0       0.000 |
|                   | OSA WO HT | 7           | 0.720 (0.399–1.299) | 1.09 0.275            | 88.2       0.000 |
| DD vs. II         | All    | 10             | 0.538 (0.204–1.419) | 1.25 0.211            | 89.3       0.000 |
|                   | All in HT | 14          | 0.364 (0.160–0.827) | 2.41 0.016            | 85.1       0.000 |
|                   | OSA with HT | 7           | 0.299 (0.104–0.864) | 2.23 0.026            | 80.8       0.000 |
|                   | OSA WO HT | 7           | 0.444 (0.130–1.515) | 1.30 0.195            | 86.5       0.000 |
| DD vs. (DI+II)    | All    | 10             | 0.720 (0.342–1.516) | 0.86 0.388            | 88.0       0.000 |
|                   | All in HT | 14          | 0.518 (0.270–0.994) | 1.98 0.048            | 83.6       0.000 |
|                   | OSA with HT | 7           | 0.441 (0.143–1.362) | 1.42 0.155            | 86.8       0.000 |
|                   | OSA WO HT | 7           | 0.593 (0.264–1.330) | 1.27 0.205            | 81.0       0.000 |
| ID vs. (DD+II)    | All    | 10             | 0.804 (0.585–1.106) | 1.34 0.181            | 53.5       0.022 |
|                   | All in HT | 14          | 0.787 (0.642–0.963) | 2.32 0.020            | 40.5       0.058 |
|                   | OSA with HT | 7           | 0.602 (0.449–0.808) | 3.38 0.001            | 36.1       0.153 |
|                   | OSA WO HT | 7           | 1.007 (0.759–1.334) | 0.05 0.964            | 9.10       0.359 |
| DD+ID vs. II      | All    | 10             | 0.664 (0.351–1.257) | 1.26 0.209            | 85.6       0.000 |
|                   | All in HT | 14          | 0.524 (0.313–0.877) | 2.46 0.014            | 79.9       0.000 |
|                   | OSA with HT | 7           | 0.407 (0.253–0.654) | 3.71 0.000            | 55.0       0.038 |
|                   | OSA WO HT | 7           | 0.657 (0.257–1.568) | 0.95 0.344            | 84.5       0.000 |
| ID vs. II         | All    | 10             | 0.695 (0.420–1.149) | 1.42 0.156            | 70.9       0.000 |
|                   | All in HT | 14          | 0.603 (0.401–0.906) | 2.43 0.015            | 59.9       0.002 |
|                   | OSA with HT | 7           | 0.448 (0.319–0.631) | 4.61 0.005            | 0.00       0.755 |
|                   | OSA WO HT | 7           | 0.778 (0.373–1.626) | 0.67 0.75             | 72.8       0.001 |

\( \text{ACE} \): angiotensin-converting enzyme; OSA: obstructive sleep apnoea; OR: odds ratio; CI: confidence interval; HT: hypertension.
indicate that the ACE I/D polymorphism plays a role in the pathogenesis of OSA with hypertension in a Chinese population. However, ACE I/D gene polymorphisms are not the only cause of OSA, and further studies are essential to elucidate the potential relationship between other genes and OSA.

Acknowledgements
The author is grateful to Dr Danhua He for her contributions to and encouragement in preparing this article. We thank Louise Adam, ELS(D), from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac) for editing the English text of a draft of this manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Jian Xu https://orcid.org/0000-0002-5014-2950
Xiaoli Li https://orcid.org/0000-0002-2157-0649

References
1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–1235.
2. Malhotra A and White DP. Obstructive sleep apnoea. Lancet 2002; 360: 237–245.
3. Liu Y, Zou J, Li X, et al. Effect of the interaction between obstructive sleep apnea and lipoprotein(a) on insulin resistance: a large-scale cross-sectional study. J Diabetes Res 2019; 2019: 9583286.
4. Gonzaga C, Bertolami A, Bertolami M, et al. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens 2015; 29: 705–712.
5. Schutz SG, Lisabeth LD, Shafie-Khorassani F, et al. Clinical phenotypes of obstructive sleep apnea after ischemic stroke: a cluster analysis. Sleep Med 2019; 60: 178–181.
6. Postrzech-Adamczyk K, Nahorecki A, Zatonska K, et al. Prevalence and risk of obstructive sleep apnea and arterial hypertension in the adult population in Poland: an observational subset of the international Prospective Urban Rural Epidemiology (PURE) study. Adv Exp Med Biol 2019; 1222: 37–42.
7. Sun J, Hu J, Tu C, et al. Obstructive sleep apnea susceptibility genes in Chinese population: a field synopsis and meta-analysis of genetic association studies. PLoS One 2015; 10: e135942.
8. De Carvalho TB, Suman M, Molina FD, et al. Relationship of obstructive sleep apnea syndrome with the 5-HT2A receptor gene in Brazilian patients. Sleep Breath 2013; 17: 57–62.
9. Pierola J, Alemany A, Yanez A, et al. NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea. Respir Med 2011; 105: 1748–1754.
10. Chen W, Ye J, Han D, et al. Association of prepro-orexin polymorphism with obstructive sleep apnea/hypopnea syndrome. Am J Otolaryngol 2012; 33: 31–36.
11. Zhou L, Xi B, Wei Y, et al. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. J Renin Angiotensin Aldosterone Syst 2012; 13: 296–304.
12. Yaren A, Oztop I, Turgut S, et al. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008; 233: 32–37.
13. Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4.
14. Zhou TB, Qin YH, Ou C, et al. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and steroid-sensitive nephrotic syndrome in children. J Renin Angiotensin Aldosterone Syst 2012; 13: 175–183.
15. Qin YH, Zhou TB, Su LN, et al. Association between ACE polymorphism and risk of IgA nephropathy: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2011; 12: 215–223.
16. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387–1388.
17. Rigat B, Hubert C, Allenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343–1346.
18. Lin P, Li H, Yu T, et al. The effect of angiotensin-convert-}
19. Pierola J, Alemany A, Yanez A, et al. NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea. Respir Med 2011; 105: 1748–1754.
10. Chen W, Ye J, Han D, et al. Association of prepro-orexin polymorphism with obstructive sleep apnea/hypopnea syndrome. Am J Otolaryngol 2012; 33: 31–36.
11. Zhou L, Xi B, Wei Y, et al. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. J Renin Angiotensin Aldosterone Syst 2012; 13: 296–304.
12. Yaren A, Oztop I, Turgut S, et al. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008; 233: 32–37.
13. Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4.
14. Zhou TB, Qin YH, Ou C, et al. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and steroid-sensitive nephrotic syndrome in children. J Renin Angiotensin Aldosterone Syst 2012; 13: 175–183.
15. Qin YH, Zhou TB, Su LN, et al. Association between ACE polymorphism and risk of IgA nephropathy: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2011; 12: 215–223.
16. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387–1388.
17. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343–1346.
18. Lin P, Li H, Yu T, et al. The effect of angiotensin-convert-{
19. Yaren A, Oztop I, Turgut S, et al. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008; 233: 32–37.
20. Yuan Y, Meng L, Zhou Y, et al. Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96: e8639.
21. Pinheiro DS, Santos RS, Jardim P, et al. The combination of ACE I/D and ACE2 G8790A polymorphisms reveals susceptibility to hypertension: a genetic association study in Brazilian patients. PLoS One 2019; 14: e221248.
22. Lee P, Douglas NJ and Riha RL. The association of angiotensin-converting enzyme gene insertion/deletion polymorphisms with OSA: a meta-analysis. Eur Respir J 2012; 40: 394–399.
23. Lan F, Cao C, Liu J, et al. Obstructive sleep apnea syndrome susceptible genes in the Chinese population: a meta-analysis of 21 case-control studies. Sleep Breath 2015; 19: 1441–1448.
24. He L, Wang B, Lang WY, et al. Genetically-reduced serum ACE activity might be a causal risk factor for obstructive
25. Lin H, Lin D, Zheng C, et al. Association of ACE I/D polymorphism with obstructive sleep apnea susceptibility: evidence based on 2,228 subjects. Sleep Breath 2014; 18: 509–516.

26. Chen G, Hu S, Lai Z, et al. Association between ACE gene I/D polymorphism and knee osteoarthritis in a Chinese population. BioSci Rep 2019; 39.

27. Zheng X, Liu G, Cui G, et al. Angiotensin-converting enzyme gene deletion polymorphism is associated with lymph node metastasis in colorectal cancer patients in a Chinese population. Med Sci Monit 2017; 23: 4926–4931.

28. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

29. Gu XQ, Liu DB, Wan GP, et al. Polymorphism of angiotensin converting enzyme genes in children with obstructive sleep apnea-syndrome. Zhong Hua Er Ke Za Zhi 2006; 44: 874–875.

30. Huang XB, Tie JH, Liu YJ, et al. Association of angiotensin-converting enzyme gene I/D polymorphism and obstructive sleep apnea hypopnea syndrome with hypertension. J Ningsxia Med Univ 2016; 38: 1112–1115, 1120.

31. Huang XB, Shao P, Wang JF, et al. Association of angiotensin-converting enzyme gene I/D polymorphism and obstructive sleep apnea hypopnea syndrome with hypertension in Hui and Han nationality in Ningxia. Ningsxia Med J 2017; 39: 326–329.

32. Li Y, Zhang W, Wang T, et al. Study on the polymorphism of angiotensin converting enzyme genes and serum angiotensin II level in patients with obstructive sleep apnea hypopnea syndrome accompanied hypertension. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004; 18: 456–459.

33. Li S, Cao J, Chen BY, et al. Investigation of the angiotensin-converting enzyme gene polymorphism in obstructive sleep apnea hypopnea syndrome. Chin J Respir Crit Care Med 2004; 3: 350–353.

34. Ping F, Zhao JC, Zhang XQ, et al. Association of the polymorphism of angiotensin converting enzyme genes with OSAS and OSAS accompanied by hypertension. Chin Gen Pract 2001; 4: 24–26.

35. Tong H, Zhang M, Dong JY, et al. Association between the angiotensin converting enzyme gene polymorphism and intermittent hypoxia during sleep with high blood pressure. Chin J Histochem Cytochem 2011; 20: 148–152.

36. Xiao Y, Huang X and Qiu C. Angiotension I converting enzyme gene polymorphism in Chinese patients with obstructive sleep apnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi 1998; 21: 489–491.

37. Zhang J, Zhao B, Gesongluobu, et al. Angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism in hypertensive patients with different degrees of obstructive sleep apnea. Hypertens Res 2000; 23: 407–411.

38. Zhang LQ, Yao WZ, He QY, et al. Association of polymorphisms in the angiotensin system genes with obstructive sleep apnea-hypopnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi 2004; 27: 507–510.

39. Song CM, Lee CH, Rhee CS, et al. Analysis of genetic expression in the soft palate of patients with obstructive sleep apnea. Acta Otolaryngol 2012; 132 Suppl 1: S63–S68.

40. Barcelo A, Elorza MA, Barbe F, et al. Angiotensin converting enzyme in patients with sleep apnoea syndrome: plasma activity and gene polymorphisms. Eur Respir J 2001; 17: 728–732.

41. Chmielewska I, Mlak R, Krawczyk P, et al. Polymorphism of the ACE gene and the risk of obstructive sleep apnoea. Pneumonol Alergol Pol 2013; 81: 207–213.

42. Lan F, Cao C, Liu J, et al. Obstructive sleep apnea syndrome susceptible genes in the Chinese population: a meta-analysis of 21 case-control studies. Sleep Breath 2015; 19: 1441–1448.